Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
Ultragenyx to Participate at Investor Conferences in March
-
TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
-
Ultragenyx Pharma (RARE) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Ultragenyx Pharma (RARE) PT Raised to $61 at TD Cowen
-
Ultragenyx to Participate at Investor Conferences in March
-
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Ultragenyx Pharma (RARE) Prices 8.33M Share and Warrant Offering at $30/sh
-
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
-
Ultragenyx Pharma (RARE) Announces Proposed $300M Share Offering
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
-
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
-
Ultragenyx Pharma (RARE) Sells Portion of Future North American Royalties on Crysvita for $500M to OMERS
-
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
-
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
-
Ultragenyx to Participate in the Cowen Health Care Conference
-
Ultragenyx to Participate in the Cowen Health Care Conference
-
Ultragenyx Pharma (RARE) PT Lowered to $124 at Cowen, Following Earnings
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Ultragenyx Pharma (RARE) Prices 4.44M Share Common Offering at $90/Sh
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Pharma (RARE) Announces Proposed $400M Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx Pharma (RARE) PT Raised to $116 at Cowen
-
Ultragenyx Pharma (RARE) PT Raised to $75 at Cowen
-
Ultragenyx Pharma (RARE) PT Raised to $79 at Cowen on Strong Crysvita Sales
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx Pharma (RARE) Prices 5.07M Share Common Offering at $60/Sh
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Cowen Starts Ultragenyx Pharma (RARE) at Outperform
-
Ultragenyx Pharma (RARE) to Offer Up to $250M in CommonStock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx Pharma (RARE) Prices 4.386M Share Common Offering at $57/Sh
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Pharma (RARE) Plans $175M Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock

